Ethical issues concerning a pay-to-participate stem cell study
Authors:
Open Access
- 19 May 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 10 (6) , 815-819
Abstract
In our critique of a pay-to-participate study, we address how the failure to disclose study-related payments appears to have violated STEM CELLS Translational Medicine's editorial policies concerning conflict-of-interest and financial disclosure. Our analysis also identifies broader ethical issues and scientific concerns related to pay-to-participate studies conducted by businesses with a record of selling purported stem cell treatments before determining whether the products they sell are safe and efficacious. Authors of peer-reviewed articles have a responsibility to comply with journal policies and disclose financial conflicts of interest to editors, reviewers, and readers. Authors should also disclose when stem cell interventions being tested in clinical trials have already been sold on a direct-to-consumer basis as “stem cell treatments” by authors' affiliate institutions. Financial conflicts of interest and other forms of possible bias must be disclosed to put clinical studies in context and facilitate the critical assessment of research methods, findings, and conclusions. The apparent failure to comply with journal editorial policies and disclose such financial conflicts warrants careful investigation.Keywords
This publication has 20 references indexed in Scilit:
- ClinicalTrials.gov, Stem Cells and ‘Pay-to-Participate’ Clinical StudiesRegenerative Medicine, 2017
- Marketing of unproven stem cell–based interventions: A call to actionScience Translational Medicine, 2017
- Placebo‐like response in absence of treatment in children with AutismAutism Research, 2017
- Autologous Cord Blood Infusions Are Safe and Feasible in Young Children with Autism Spectrum Disorder: Results of a Single-Center Phase I Open-Label TrialStem Cells Translational Medicine, 2017
- Patient-Funded Trials: Opportunity or Liability?Cell Stem Cell, 2015
- Clinical research: Should patients pay to play?Science Translational Medicine, 2015
- Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autismJournal of Translational Medicine, 2013
- Pay-to-Participate Funding Schemes in Human Cell and Tissue Clinical StudiesRegenerative Medicine, 2012
- Commercial Features of Placebo and Therapeutic EfficacyJAMA, 2008
- Placebo Effects of Marketing Actions: Consumers May Get What They Pay ForJournal of Marketing Research, 2005